Pantoprazol Generis (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Generis, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and Zollinger‑Ellison syndrome in adults. GNH USA supplies Pantoprazol Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Generis is a proton pump inhibitor that acts on gastric acid secretion pathways. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive esophagitis: accelerates mucosal healing and reduces risk of complications. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - Prevention of NSAID‑induced gastric ulcers: lowers ulcer incidence in patients requiring long‑term NSAID therapy.

Pantoprazol Generis may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Acute interstitial nephritis: kidney inflammation causing reduced urine output. - Severe hypersensitivity reactions: rash, angio‑edema or anaphylaxis. - Osteoporotic fractures: increased risk of hip, wrist or vertebral fractures with long‑term use. - Low magnesium (hypomagnesemia): muscle cramps, tremor, cardiac arrhythmia. - Liver enzyme elevation: increased ALT/AST levels indicating hepatic stress.

When prescribing Pantoprazol Generis, clinicians should consider several safety aspects: - Assess renal function: adjust use in patients with severe impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Monitor long‑term therapy: consider bone health assessment after 12 months of continuous use. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Pantoprazol Generis can affect the pharmacokinetics of several co‑administered medicines. Awareness of key interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption due to increased gastric pH. - Atazanavir: markedly decreased plasma concentrations, compromising HIV treatment. - Clopidogrel: diminished antiplatelet effect, raising thrombotic risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: slight rise in serum levels; observe for toxicity signs. - Methotrexate: enhanced exposure, especially at high doses.